You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma
SBC: NUVOX PHARMA, L.L.C. Topic: 102Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An Integrated Microarray Printing and Detection System
SBC: BIOSENSING INSTRUMENT INC Topic: 400DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER
SBC: PAPGENE, INC. Topic: NCIThis proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Yeast based Immunotherapy against Clostridium difficile Infection
SBC: FZATA INC Topic: NIAIDAbstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Discovery of inhibitors of Zika virus
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDPROJECT SUMMARY Novel inhibitors of Zika virusZIKVare urgently needed to prevent the occurrence of virus induced microcephaly and Guillain BarrsyndromeThe objective of this Phase I SBIR feasibility study is to identify drug like compounds that specifically inhibit ZIKV replicationDuring the course of this Phase I funding periodwe will execute hit finding campaign against a library ofcompounds with ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Genome Mining the Full Diversity of the Actinomycete Biosynthetic Universe for Neomorph Antibiotic Discovery
SBC: WARP DRIVE BIO, LLC Topic: NIAIDABSTRACT To combat multidrug resistant bacterial infections novel classes of antibiotics with new mechanisms of action are desperately required Genome mining for novel natural products is quickly replacing traditional approaches to antibiotic discovery Warp Drive Bio has sequenced over actinomycete strain genomes from diverse sources worldwide and our proprietary genomic database conta ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
SBC: TSRL, INC. Topic: NIAIDAbstract Yearly influenza epidemics strike millions of peoplecausing up todeathsFatality caused by most seasonal influenza viruses is ltbut with significant mortality in the young and the elderly populationsWhen a new pathogenic influenza strain enters the populationa pandemic could kill tens of millions of people with a negative economic impact estimated to be overbillion dollarsInfluenza virus i ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Strategies to Improve Production of a Full Length Native HIV Env Spike
SBC: CODEX BIOSOLUTIONS Topic: RProject Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Selection of a device for intranasal administration of a mucosal vaccine for HSV
SBC: Biomedical Research Models, Inc. Topic: RGlobally an estimated of the human population is infected with HSV including andgt of the U S adult population Genital herpes is associated with an increased risk of HIV acquisition and transmission of HSV infection can cause neonatal herpes with high infant mortality HSV infection in the adult population has increased substantially in the past two decades despite the availabil ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Serotype independent therapeutic vaccine for Streptococcus pneumoniae
SBC: Integrated Biotherapeutics, Inc. Topic: RIn the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health